This company seems to have been delisted
Reason: Acquired by Amgen
Last recorded trade on: November 25, 2022
Source: https://www.amgen.com/newsroom/press-releases/2022/08/amgen-to-acquire-chemocentryx-for-$4-billion-in-cash
Reason: Acquired by Amgen
Last recorded trade on: November 25, 2022
Source: https://www.amgen.com/newsroom/press-releases/2022/08/amgen-to-acquire-chemocentryx-for-$4-billion-in-cash
ChemoCentryx
CCXI
$92.89
Share price
0.00%
Change (1 day)
43.71%
Change (1 year)
Categories
Revenue for ChemoCentryx (CCXI)
Revenue in 2022 (TTM): NZ$55.81 Million
According to ChemoCentryx's latest financial reports the company's current revenue (TTM 
) is NZ$66.46 Million. In 2021 the company made a revenue of NZ$46.7 Million a decrease over the revenue in the year 2020 that were of NZ$89.24 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for ChemoCentryx from 2011 to 2022
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2022 (TTM) | NZ$55.81 M | 19.52% |
| 2021 | NZ$46.7 M | -47.67% |
| 2020 | NZ$89.24 M | 67.18% |
| 2019 | NZ$53.38 M | -16.48% |
| 2018 | NZ$63.91 M | -44.97% |
| 2017 | NZ$0.11 B | 603.65% |
| 2016 | NZ$16.5 M | |
| 2015 | N/A | |
| 2014 | N/A | -100% |
| 2013 | NZ$7.37 M | 11.95% |
| 2012 | NZ$6.58 M | -83.77% |
| 2011 | NZ$40.58 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | NZ$17.28 B | 25,910.48% | 🇺🇸 USA |
 | NZ$100.65 B | 151,335.48% | 🇺🇸 USA |
 | NZ$71.79 B | 107,912.25% | 🇬🇧 UK |
 | NZ$86.29 B | 129,738.71% | 🇺🇸 USA |
 | NZ$158.69 B | 238,666.13% | 🇺🇸 USA |
 | NZ$59.71 B | 89,749.46% | 🇺🇸 USA |
 | NZ$113.68 B | 170,937.63% | 🇺🇸 USA |
 | NZ$29.55 B | 44,370.43% | 🇮🇱 Israel |
 | NZ$114.64 B | 172,394.62% | 🇺🇸 USA |